Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961236 | 0.92 | DDR1 (0.43) | DDR1CA12CA9AR | |
| SCHEMBL2389752 | 0.88 | CA12 (0.39) | DDR1CA12CA9AR | |
| SCHEMBL961805 | 0.88 | CA12 (0.39) | DDR1CA12CA9AR | |
| SCHEMBL2389692 | 0.88 | CA12 (0.39) | DDR1CA12CA9AR | |
| SCHEMBL1661215 | 0.87 | DDR1 (0.40) | DDR1CA12CA9AR | |
| SCHEMBL1660345 | 0.86 | CA12 (0.38) | DDR1CA12CA9AR | |
| SCHEMBL2597158 | 0.85 | DDR1 (0.36) | DDR1CA12CA9AR | |
| SCHEMBL1001067 | 0.85 | DDR1 (0.36) | DDR1CA12CA9AR | |
| SCHEMBL2391523 | 0.84 | DDR1 (0.41) | DDR1CA12CA9AR | |
| SCHEMBL1661057 | 0.84 | AR (0.36) | DDR1CA12CA9AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | claimed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | claimed |
| EP-2585070-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | claimed |
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | claimed |
| WO-2013036224-A1 | USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | claimed |
| EP-2490691-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| WO-2011161249-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | claimed |
| WO-2011048150-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | claimed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| WO-2010046399-A1 | COMBINATIONS FOR THE TREATMENT OF MIGRAINE | NOVARTIS AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | DDR1 1011/4885CA12 2397/4885CA9 2844/4885 |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | GRM1, GRIK2, GRIK1 | DDR1 2209/4885CA12 3842/4885CA9 4292/4885 |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | GRIK1, GRIK2, GRIK4 | DDR1 1095/4885CA12 720/4885CA9 1726/4885 |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | DDR1 1011/4885CA12 2397/4885CA9 2844/4885 |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | CLN6, GBA1, GBA2 | DDR1 2239/4885CA12 4310/4885CA9 4490/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | DDR1 3161/4885CA12 3261/4885CA9 3458/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | DDR1 2722/4885CA12 3678/4885CA9 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.